Bevacizumab Added to Chemo Tested in Children With Metastatic Sarcoma
A Phase 2 trial examines whether adding the anti-angiogenic drug bevacizumab to standard chemo improves outcomes in pediatric sarcoma.
Summary
This completed Phase 2 trial enrolled children and adolescents with metastatic rhabdomyosarcoma or non-rhabdomyosarcoma soft tissue sarcoma. Sponsored by Hoffmann-La Roche, the study randomly assigned patients to receive either standard chemotherapy alone or standard chemotherapy combined with bevacizumab, a drug that blocks blood vessel growth in tumors. Treatment ran for roughly one to two years, consisting of an induction phase of nine three-week cycles followed by a maintenance phase of twelve four-week cycles. The goal was to evaluate whether adding bevacizumab — already approved in adult cancers — could safely improve responses in a pediatric population where treatment options remain limited and prognosis for metastatic disease is poor.
Detailed Summary
Soft tissue sarcomas in children and adolescents, particularly metastatic rhabdomyosarcoma, carry a grim prognosis. Standard chemotherapy regimens achieve limited long-term survival in metastatic settings, creating urgent need for novel combination approaches. This trial explored whether adding bevacizumab, a VEGF-targeting monoclonal antibody that starves tumors of blood supply, could meaningfully improve outcomes beyond chemotherapy alone.
This open-label, randomized, two-arm Phase 2 study enrolled pediatric and adolescent patients with metastatic rhabdomyosarcoma or non-rhabdomyosarcoma soft tissue sarcoma. Participants were assigned to receive either standard chemotherapy or standard chemotherapy plus bevacizumab. The induction phase comprised nine three-week cycles with bevacizumab dosed at 7.5 mg/kg intravenously on day one of each cycle. Maintenance followed with twelve four-week cycles, during which bevacizumab was dosed at 5 mg/kg on days one and fifteen. Total treatment duration was approximately one to two years.
The primary aims were to assess the safety profile and efficacy of the combination regimen versus chemotherapy alone. Bevacizumab has demonstrated anti-tumor activity in adult solid tumors, but its role in pediatric sarcomas was not well established at the time of trial initiation in 2008. Evaluating anti-angiogenic strategies in children carries additional considerations around developmental toxicity and long-term safety.
The trial has been completed, though detailed results are not available from the abstract alone. Findings from studies like this inform whether anti-angiogenic intensification of chemotherapy is a viable path forward in pediatric oncology.
Caveats are significant: this summary is based solely on the trial registration abstract, and no outcome data, adverse event rates, or conclusions can be reported here. The trial dates to 2008, and any practice-changing conclusions would require review of the full published results and subsequent evidence.
Key Findings
- Phase 2 trial tested bevacizumab plus standard chemotherapy vs chemotherapy alone in pediatric metastatic sarcoma.
- Bevacizumab was dosed at 7.5 mg/kg during induction and 5 mg/kg during maintenance phases.
- Treatment spanned up to two years across induction and maintenance cycles.
- Trial included both rhabdomyosarcoma and non-rhabdomyosarcoma soft tissue sarcoma subtypes.
- No efficacy or safety outcome data available from the abstract registration alone.
Methodology
Open-label, randomized two-arm Phase 2 study sponsored by Hoffmann-La Roche. Pediatric and adolescent patients with metastatic soft tissue sarcoma were randomized to standard chemotherapy with or without bevacizumab across induction (9 x 3-week cycles) and maintenance (12 x 4-week cycles) phases. The trial was registered in 2008 and has since been completed.
Study Limitations
This summary is based on the trial registration abstract only and no outcome, safety, or efficacy data can be reported. The trial was initiated in 2008 and its full results, if published, would require separate review to assess clinical implications. Absence of reported endpoints limits any conclusions about bevacizumab's benefit in this population.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: